# Experimental Therapeutics Program

> **NIH NIH P30** · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $48,982

## Abstract

10.0 Abstract: Experimental Therapeutics (ET) Program
The overarching goal of ET is to develop and test new therapies for solid tumors and hematologic malignancies
based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET
members to early-stage clinical testing and also on providing platforms for investigators in other programs to
evaluate their findings in clinical settings. To achieve this mission, the program focuses on three specific aims:
Aim 1: Target detection and measurement—Investigate diagnostic advances, including molecular early
detection, liquid biopsy and imaging, to guide new treatment approaches and assessments of response; Aim 2:
Molecular targeting: Development and preclinical and clinical testing—Investigate new cancer therapies
based on novel molecular targets in in vitro and in vivo laboratory studies as well as early phase clinical trials;
and Aim 3: Treatment delivery: Novel delivery strategies—Investigate the development of new technologies
for therapy delivery, including molecular carriers, nanotechnology, and novel radiation therapy and radiation
protection approaches. To achieve these three aims, members of ET are supported by extensive expertise
available in other University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
(UMGCCC) Programs to translate basic research findings to the clinic and by the availability of exceptional
shared services. The ET Program has 56 members, including 31 full members and 25 associate members, who
conduct cancer-focused research that receives $14.6 million direct cost annual funding ($19.4 million total),
including $3.6 million (25%) from NCI and $4.1 million from other peer-reviewed sources. ET Program members
receive $6.9 million annually from non-peer-reviewed funding sources. During this funding period, ET members
authored 889 cancer-related publications, of which 22% resulted from intraprogrammatic, 21% from
interprogrammatic, and 8% from intra- and interprogrammatic collaborations. Of the 889 publications, 72%
include collaborations with external investigators, reflecting the high national impact of the ET Program. A high
percentage of ET publications (14%) were in journals with an impact factor ≥10. Research efforts of ET members
are supported by extensive use of all shared services. The ET Program collaborates with the other four UMGCCC
research programs and facilitate community outreach and engagement (COE) to identify and address the cancer
research priorities of the catchment area.

## Key facts

- **NIH application ID:** 10267041
- **Project number:** 2P30CA134274-14
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** MARIA R BAER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $48,982
- **Award type:** 2
- **Project period:** 2008-08-08 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10267041

## Citation

> US National Institutes of Health, RePORTER application 10267041, Experimental Therapeutics Program (2P30CA134274-14). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10267041. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*